New Drugs and Clinical Trials · eu
Lorecivivint Enters EMA Review as Knee Osteoarthritis Drug Seeks to Modify Disease Progression
Can it provide evidence of improved joint structure alongside relief from knee pain? Biosplice supports its application with two years of imaging follow-up, but confirmation that the submission is complete is only the starting point for review; efficacy and safety remain to be assessed.
For patients with knee osteoarthritis, reducing pain and slowing joint damage are related but distinct treatment goals. Lorecivivint (LOR), an investigational drug developed by Biosplice, is attempting to address both. On October 2, the company announced that the European Medicines Agency (EMA) had confirmed on September 30 that its marketing authorization application was complete, initiating the centralized review procedure.
This development brings LOR under review in the European Union following the United Kingdom. According to the company announcement, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) confirmed on August 28 that the application was complete. However, such confirmation is a procedural threshold and does not mean that regulators have endorsed its efficacy, safety, or disease-modifying claims; LOR has not yet been approved for marketing.
LOR is a small-molecule suspension formulation injected directly into the knee joint. Its development program spans 11 clinical trials and has tested dosing once a year or once every six months. It targets two kinases, DYRK1A and CLK2. The company's proposed biological rationale is that inhibiting the relevant activity reduces inflammation and cartilage breakdown and modulates Wnt signaling associated with chondrocyte function; these mechanisms must still be interpreted separately from clinical benefits.
One of the core pieces of evidence supporting this application comes from the Phase 3 OA-07 trial. In its original announcement and the same press release published by TMCnet, Biosplice stated that medial knee joint-space width in patients receiving annual LOR injections was initially maintained and subsequently increased during two years of follow-up; patients who received placebo in the first year and then switched to LOR also showed an increase in joint-space width. This is the company's description of the imaging results, not an EMA review conclusion.
Joint-space width provides clues to structural changes; an increase in joint-space width alone cannot establish that cartilage has regenerated. Citing EMA guidance on osteoarthritis trials, the announcement noted that X-ray measurements of joint-space width using standardized methods can be used to assess structural damage, but their precision is affected by imaging technique, and structural studies should also include at least two years of follow-up. In addition, once the placebo group switched to the drug, subsequent changes lacked a continuing placebo control, limiting interpretation of the two-year results.
Regarding symptoms, the company said that in OA-07, the LOR group showed improved pain scores at six months and improvements in both pain and function at twelve months compared with the placebo group. However, the body of the announcement did not provide complete effect sizes, confidence intervals, or adverse event data, making it difficult for readers to assess the magnitude of improvement and the risks. The original announcement and the republished content also originated from the same company and cannot be regarded as two independent validations.
The forthcoming review will examine whether these imaging, pain, function, and safety data together support the proposed treatment claims in the application. For patients, this news means that a new drug seeking to modify disease progression is beginning formal evaluation; a substantive evidence hurdle remains before the magnitude and duration of its clinical benefits can be established.